Company: SWKH
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0001628280-25-013989
Chunk: 137

Company: SWK Holdings Corp
Filing Date: 2025-03-20
Form: 10-K
Item: Item 7
Chunk 137
---
 and per share data):

Royalty PurchasesLicensed TechnologyFunded AmountGAAP BalanceRevenue RecognizedBesivance® (1)Ophthalmic antibiotic$6,000 $— $29 Best ABT, Inc.(2), (3)Oncology diagnosis 5,784 2,347 — Coflex®/Kybella®Spinal stenosis/submental fullness4,350 3,053 246 Cambia® (4)NSAID migraine treatment 8,500 — 420 Duo RoyaltyJapanese Women's health/cystic fibrosis15,353 11,231 2,346 Flowonix Medical, Inc.(3),(5)Drug delivery device 12,455 8,433 — Forfivo XL®Depressive disorder treatment6,000 1,267 1,239 Ideal Implant, Inc. (3), (6)Aesthetics 4,025 3,050 — Immune GlobulinImmune Globulin Therapeutics 14,100 11,685 1,729 Iluvien® Diabetic macular edema16,501 15,865 1,774 ReliefRare Disease Portfolio7,701 8,005 490 Veru, Inc(7)Women's health10,000 — 582 

22

Term LoansTypeMaturity DatePrincipalGAAP BalanceRateRevenue Recognized4Web, Inc.First lien6/30/25$23,736 $26,482 11.3 %$4,722 AOTI, Inc.First lien3/21/278,478 8,635 11.2 %1,895 BIOLASE, Inc. (2) (3)First lien5/31/251,000 1,000 10.3 %916 Biotricity, Inc.First lien2/15/2714,446 14,749 11.5 %2,387 CDMO ManufacturerFirst lien9/13/275,000 5,298 13.3 %806 Elutia, Inc.First lien8/10/2721,045 23,944 12.0 %3,767 Epica International, Inc.First lien7/23/24— — 11.5 %957 Eton Pharmaceuticals, Inc